Amaç: Kronik hastalık bakımında temel yaklaşım tedaviye uyumun sağlanmasını içermektedir. Tedaviye uyumun sağlanması bireylerin yaşam kalitesini artırmak bakımından önem arz etmektedir. Kronik bir hastalık olan Multiple Skleroz (MS), başarılı bir tedavi süreci için tedaviye uyumun son derece önemli olduğu bir hastalıktır. Bu araştırma, MS’te tedaviye uyumunun belirlenmesi amacıyla tanımlayıcı olarak yapılmıştır. Yöntem: Araştırmanın evrenini Nisan 2020-Şubat 2021 tarihleri arasında çalışmaya katılan 164 MS hastası oluşturmuştur. Veriler bireylerin sosyodemografik ve hastalığa ilişkin özellikleri belirleyen Tanıtıcı Bilgi Formu ve Multiple Skleroz Tedaviye Uyum Anketi (MS-TAQ) kullanılarak çevrimiçi toplanmıştır. Verilerin analizinde yüzdelik ve ortalama hesaplamaları, Kruskal Wallis testi ve Spearman korelasyon analizi kullanılmıştır. Bulgular: Katılımcıların %72.6’sının kadın, %50.6’sının 30-41 yaş aralığında olduğu, %66.5’inin evli, %48.2’sinin MS tipini bilmediği, %38.4’ünün Relapsing Progresif MS tipine sahip olduğu, %20.1’inin ise İnterferon Beta 1a (cilt altı enjeksiyon) tedavisi uyguladığı belirlenmiştir. Engeller alt boyut ortalama puanının 9.72±8.17, yan etkiler alt boyutunun 9.21±11.46, başetme stratejileri alt boyutunun 1.09±1.87 olduğu belirlenmiştir. Katılımcılar enjeksiyon yan etkilerinin çok önemli bir engel olduğunu, tedavi sonrasında üşüme, titreme, baş ağrısı ya da grip benzeri semptomları her zaman yaşadıklarını ve tedaviyi uygulamadan önce ağrıyı azaltmak için ilaç alma yöntemini en çok kullandıkları başetme stratejisi olarak bildirmişlerdir. Sonuç: MS hastalarının tedavi uyumu yüksek olmasına rağmen desteklenmesi gereken bir durum olarak öne çıkmaktadır. Öte yandan tedavi sürecinde hastaların uyumunu en çok güçleştiren durum tedavi sonrası oluşan semptomlarla başetme stratejilerini yeterince geliştirememiş olmalarıdır.
Aim: The basic approach in chronic disease care includes ensuring compliance with treatment. Ensuring adherence to treatment is important in terms of increasing the quality of life of individuals. Multiple Sclerosis (MS), a chronic disease, is a disease in which adherence to treatment is extremely important for a successful treatment process. This study was conducted as a descriptive study to determine treatment compliance in MS. Method: The population of the study consisted of 164 MS patients who participated to the study between April 2020 and February 2021. Data were collected online using the Introductory Information Form, which determines the sociodemographic and disease-related characteristics of the individuals, and the Multiple Sclerosis Treatment Adherence Questionnaire (MS-TAQ). Percentage and mean calculations, Kruskal Wallis test and Spearman correlation analysis were used in the analysis of the data. Results: It was determined that 72.6% of the participants were female, 50.6% were between the ages of 30-41, 66.5% were married, 48.2% did not know the type of MS, 38.4% had Relapsing Progressive MS, 20.1% applied Interferon Beta 1a (subcutaneous injection) treatment. It was determined that the barriers sub-dimension mean score was 9.72±8.17, the side effects sub-dimension 9.21±11.46, and the Coping Strategies sub-dimension 1.09±1.87. Participants reported that injection side effects were a very important obstacle, that they always experienced chills, flicker, headaches or flu-like symptoms after treatment, and that taking medication to reduce pain before administering the treatment was their most common coping strategy. Conclusion: Despite the high compliance of MS patients with treatment, it stands out as a condition that should be supported. On the other hand, the most difficult situation for patients to adapt during the treatment process is that they could not adequately develop strategies to cope with the symptoms that occur after the treatment.
Primary Language | Turkish |
---|---|
Subjects | Health Care Administration |
Journal Section | Articles |
Authors | |
Early Pub Date | April 5, 2024 |
Publication Date | April 30, 2024 |
Submission Date | April 4, 2023 |
Acceptance Date | September 11, 2023 |
Published in Issue | Year 2024 Volume: 17 Issue: 1 |
MEU Journal of Health Sciences Assoc was began to the publishing process in 2008 under the supervision of Assoc. Prof. Gönül Aslan, Editor-in-Chief, and affiliated to Mersin University Institute of Health Sciences. In March 2015, Prof. Dr. Caferi Tayyar Şaşmaz undertook the Editor-in Chief position and since then he has been in charge.
Publishing in three issues per year (April - August - December), it is a multisectoral refereed scientific journal. In addition to research articles, scientific articles such as reviews, case reports and letters to the editor are published in the journal. Our journal, which has been published via e-mail since its inception, has been published both online and in print. Following the Participation Agreement signed with TÜBİTAK-ULAKBİM Dergi Park in April 2015, it has started to accept and evaluate online publications.
Mersin University Journal of Health Sciences have been indexed by Turkey Citation Index since November 16, 2011.
Mersin University Journal of Health Sciences have been indexed by ULAKBIM Medical Database from the first issue of 2016.
Mersin University Journal of Health Sciences have been indexed by DOAJ since October 02, 2019.
Article Publishing Charge Policy: Our journal has adopted an open access policy and there is no fee for article application, evaluation, and publication in our journal. All the articles published in our journal can be accessed from the Archive free of charge.
This work is licensed with Attribution-NonCommercial 4.0 International.